US89532E2081 - Common Stock
TREVENA INC
NASDAQ:TRVN (4/17/2024, 7:00:01 PM)
Premarket: 0.4422 +0.04 (+10%)0.402
+0.01 (+2.29%)
Trevena, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. The company is headquartered in Chesterbrook, Pennsylvania and currently employs 35 full-time employees. The company went IPO on 2014-01-31. The firm is focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The firm's product, OLINVYK (oliceridine) injection, is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The company is also engaged in three differentiated investigational drug candidates: TRV045, TRV250, and TRV734. TRV045 is a novel sphingosine-1-phosphate (S1P), receptor modulator that may offer a new, non-opioid approach to managing chronic pain, as well as treating epilepsy and seizure disorders. TRV250 is a G-protein biased delta-opioid receptor (DOR), agonist as a compound with a mechanism for the treatment of acute migraine. TRV734 is a new chemical entity (NCE) targeting the same mechanism of action at the mu-opioid receptor (MOR). TRV734 is used for the treatment of opioid use disorder.
TREVENA INC
955 Chesterbrook Boulevard, Suite 110
Chesterbrook PENNSYLVANIA 19087
P: 16103548840
CEO: Carrie L. Bourdow
Employees: 35
Website: https://www.trevena.com/
Get insights into the top gainers and losers of Wednesday's after-hours session.
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies Company...
Trevena (TRVN) files prospectus for the resale of 2.78M shares of common stock by selling stockholders.
Pre-market stock movers are worth checking out on Tuesday to catch up on all of the hottest stock market news for this morning!
CHESTERBROOK, Pa., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on...
Trevena (TRVN) announces agreements for the sale of shares and warrants, expected to generate $4M in gross proceeds.
Here you can normally see the latest stock twits on TRVN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: